We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
Cap. Flow
-$103M
Cap. Flow %
-4.19%
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.4M
2
MRK icon
Merck
MRK
+$20M
3
WELL icon
Welltower
WELL
+$14.4M
4
CI icon
Cigna
CI
+$9.62M
5
LLY icon
Eli Lilly
LLY
+$9.59M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
VTRS icon
Viatris
VTRS
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.43%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
151
Wave Life Sciences
WVE
$1.13B
$1.18M 0.05%
+30,336
New +$1.23M
QURE icon
152
uniQure
QURE
$2.93B
$1.18M 0.05%
19,751
-17,990
-48% -$804K
AVDL
153
DELISTED
Avadel Pharmaceuticals
AVDL
$1.17M 0.05%
814,588
– –
RDY icon
154
Dr. Reddy's Laboratories
RDY
$9.85B
$1.17M 0.05%
144,750
-37,750
-21% -$287K
TTPH
155
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.15M 0.05%
42,966
– –
VKTX icon
156
Viking Therapeutics
VKTX
$3.86B
$1.13M 0.05%
114,016
+57,008
+100% +$477K
FOMX
157
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.13M 0.05%
300,781
-300,424
-50% -$1.13M
LIVN icon
158
LivaNova
LIVN
$4.45B
$1.11M 0.05%
11,400
– –
AFMD
159
DELISTED
Affimed
AFMD
$1.07M 0.04%
25,400
– –
PRGO icon
160
Perrigo
PRGO
$1.43B
$1.05M 0.04%
21,718
-15,582
-42% -$729K
MRTX
161
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$996K 0.04%
13,590
– –
ALLK
162
DELISTED
Allakos
ALLK
$989K 0.04%
+24,414
New +$987K
ADAP
163
DELISTED
Adaptimmune Therapeutics
ADAP
$983K 0.04%
228,496
– –
HOLX
164
DELISTED
Hologic
HOLX
$946K 0.04%
19,546
– –
OVID icon
165
Ovid Therapeutics
OVID
$442M
$880K 0.04%
496,977
– –
ACIU icon
166
AC Immune
ACIU
$241M
$868K 0.04%
171,813
– –
MTEM
167
DELISTED
Molecular Templates, Inc.
MTEM
$837K 0.03%
9,607
– –
INGN icon
168
Inogen
INGN
$174M
$763K 0.03%
8,000
-5,500
-41% -$686K
CYH icon
169
Community Health Systems
CYH
$391M
$761K 0.03%
203,935
– –
SNDX icon
170
Syndax Pharmaceuticals
SNDX
$1.73B
$753K 0.03%
143,438
-56,562
-28% -$323K
XRN
171
Chiron Real Estate Inc
XRN
$516M
$721K 0.03%
14,680
– –
MNK
172
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$717K 0.03%
32,980
-20,620
-38% -$440K
MYGN icon
173
Myriad Genetics
MYGN
$507M
$682K 0.03%
+20,549
New +$626K
RYTM icon
174
Rhythm Pharmaceuticals
RYTM
$7.25B
$682K 0.03%
24,890
– –
WHWK
175
Whitehawk Therapeutics
WHWK
$190M
$667K 0.03%
49,333
-1,667
-3% -$71.7K
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.

  • Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
  • Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
  • Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
  • Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
  • Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
  • Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.